bioengineering

Reports say epigenetic editing — altering gene activity without changing DNA sequence — is moving closer to clinical application as the bioengineering tools behind it mature. Unlike CRISPR-style gene cutting, epigenetic approaches aim to switch genes on or off reversibly, and researchers see growing potential for treating disease with fewer permanent risks. The field is watching which tools and trials will translate first.